Literature DB >> 23322500

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.

Enrique Alvarez1, Laura Piccio, Robert J Mikesell, Eric C Klawiter, Becky J Parks, Robert T Naismith, Anne H Cross.   

Abstract

CXCL13, a B-cell chemokine, has been proposed as a biomarker in a variety of conditions, some of which can mimic multiple sclerosis and can have very high levels. In this case-control study, cerebrospinal fluid (CSF) CXCL13 was elevated in multiple sclerosis, neuromyelitis optica and other inflammatory neurological controls compared with noninflammatory controls. Levels did not differentiate disease groups. For all subjects taken together, CSF CXCL13 correlated with CSF WBC, oligoclonal band numbers, CSF protein, EDSS, and neurofilament levels. In subgroup analyses, CSF CXCL13 correlated with CSF WBC in neuromyelitis optica and IgG index in multiple sclerosis. Additionally, serum CXCL13 was elevated in neuromyelitis optica.

Entities:  

Keywords:  CXCL13; Multiple sclerosis; biomarker; myelin basic protein; neurofilament; neuroinflammation; neuromyelitis optica

Mesh:

Substances:

Year:  2013        PMID: 23322500      PMCID: PMC3959125          DOI: 10.1177/1352458512473362

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  10 in total

1.  Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Authors:  R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

2.  Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

Authors:  Mohsen Khademi; Ingrid Kockum; Magnus L Andersson; Ellen Iacobaeus; Lou Brundin; Finn Sellebjerg; Jan Hillert; Fredrik Piehl; Tomas Olsson
Journal:  Mult Scler       Date:  2010-12-06       Impact factor: 6.312

3.  Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.

Authors:  R Takano; T Misu; T Takahashi; S Sato; K Fujihara; Y Itoyama
Journal:  Neurology       Date:  2010-07-20       Impact factor: 9.910

4.  Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica.

Authors:  Xiaonan Zhong; Honghao Wang; Yongqiang Dai; Aimin Wu; Jian Bao; Wen Xu; Chen Cheng; Zhengqi Lu; Wei Qiu; Xueqiang Hu
Journal:  J Neuroimmunol       Date:  2011-10-28       Impact factor: 3.478

5.  Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

Authors:  Markus Krumbholz; Diethilde Theil; Sabine Cepok; Bernhard Hemmer; Pia Kivisäkk; Richard M Ransohoff; Monika Hofbauer; Cinthia Farina; Tobias Derfuss; Caroline Hartle; Jia Newcombe; Reinhard Hohlfeld; Edgar Meinl
Journal:  Brain       Date:  2005-11-09       Impact factor: 13.501

6.  A prospective study on the role of CXCL13 in Lyme neuroborreliosis.

Authors:  C Schmidt; A Plate; B Angele; H-W Pfister; M Wick; U Koedel; T A Rupprecht
Journal:  Neurology       Date:  2011-03-22       Impact factor: 9.910

7.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

8.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

9.  Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

Authors:  Toshiyuki Takahashi; Kazuo Fujihara; Ichiro Nakashima; Tatsuro Misu; Isabelle Miyazawa; Masashi Nakamura; Shohei Watanabe; Yusei Shiga; Chihiro Kanaoka; Juichi Fujimori; Shigeru Sato; Yasuto Itoyama
Journal:  Brain       Date:  2007-04-19       Impact factor: 13.501

10.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08
  10 in total
  36 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 2.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

3.  MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia.

Authors:  Jian-Qin Li; Shao-Yan Hu; Zhao-Yue Wang; Jing Lin; Su Jian; Yong-Chao Dong; Xiao-Fang Wu; Dai Lan; Li-Juan Cao
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

Review 4.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

5.  CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients.

Authors:  Judith N Wagner; S Weis; C Kubasta; J Panholzer; T J von Oertzen
Journal:  J Neurol       Date:  2017-11-13       Impact factor: 4.849

6.  CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis.

Authors:  Maria Chiara Trolese; Alessandro Mariani; Mineko Terao; Massimiliano de Paola; Paola Fabbrizio; Francesca Sironi; Mami Kurosaki; Silvia Bonanno; Silvia Marcuzzo; Pia Bernasconi; Francesca Trojsi; Eleonora Aronica; Caterina Bendotti; Giovanni Nardo
Journal:  EBioMedicine       Date:  2020-11-09       Impact factor: 8.143

Review 7.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

8.  Altered Expression of CXCL13 and CXCR5 in Intractable Temporal Lobe Epilepsy Patients and Pilocarpine-Induced Epileptic Rats.

Authors:  Ruohan Li; Limin Ma; Hao Huang; Shu Ou; Jinxian Yuan; Tao Xu; Xinyuan Yu; Xi Liu; Juan Yang; Yangmei Chen; Xi Peng
Journal:  Neurochem Res       Date:  2016-11-21       Impact factor: 3.996

Review 9.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

10.  Gene expression changes in aging retinal microglia: relationship to microglial support functions and regulation of activation.

Authors:  Wenxin Ma; Radu Cojocaru; Norimoto Gotoh; Linn Gieser; Rafael Villasmil; Tiziana Cogliati; Anand Swaroop; Wai T Wong
Journal:  Neurobiol Aging       Date:  2013-04-19       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.